 |
Clinical Trials |
| Glaucoma |
|
Disease/ Subspecialty:
Glaucoma
Principal Investigator:
Ronald Gross, M.D.
Contact:
email Glaucoma-trials@bcm.tmc.edu
or call (713)798-4123
Enrollment:
No
Sponsor:
Allergan
Title:
A 48-month multi-center, randomized, double-masked, placebo-controlled, clinical study to evaluate the effectiveness and safety of oral Mematine in daily doses of 20MG and 10 MG in patients with chronic open-angle glaucoma at risk for glaucomatous progression.
IRB Protocol #:
H-7769
|
 |
Disease/ Subspecialty:
Glaucoma
Principal Investigator:
Silvia Orengo-Nania, M.D.
Contact:
email Glaucoma-trials@bcm.tmc.edu
or call (713)798-4123
Enrollment:
No
Sponsor:
Alcon
Title:
Study of the safety and efficacy of Travoprost 0.004%/Timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
IRB Protocol #:
H-12607
|
|
Disease/ Subspecialty:
Pediatric Glaucoma
Principal Investigator:
David Coats, M.D.
Contact:
email Pedi_Glaucoma-trials@bcm.tmc.edu
or call (832)822-3230
Enrollment:
No
Sponsor:
Merck
Title:
Three month, double-masked, active treatment controlled, multi-center study of 2% Dorzolamide T.I.D. and of Timolol Maleate in gel-forming solution Q.D. in pediatric patients age less than 6 years with intraocular pressure or glaucoma.
IRB Protocol #:
H-9277
|
|
Disease/ Subspecialty:
Glaucoma
Principal Investigator:
Silvia Orengo-Nania, M.D.
Contact:
email Glaucoma-trials@bcm.tmc.edu
or call (713) 798-4123
Enrollment:
No
Sponsor:
Alcon
Title:
A three month multi-center, double-masked study of safety and efficacy of Travoprost 0.004% / Timolol 0.5% ophthalmic solution compared to Travatan® and Timolol 0.5% in subjects with open-angle glaucoma or ocular hypertension.
IRB Protocol #:
H-12629
|
|
Disease/ Subspecialty:
Glaucoma
Principal Investigator:
Ronald Gross, M.D.
Contact:
email Glaucoma-trials@bcm.tmc.edu
or call (713) 798-4123
Enrollment:
No
Sponsor:
Allergan
Title:
A multi-center, double-masked, random, 3-arm, parallel study for three months (with a nine-month masked extension) of the safety and efficacy of Bimatoprost 0.03%/ Timolol 0.5% combination ophthalmic solution once daily compared with Timolol 0.5% monotherapy twice daily and Bimatoprost 0.03% monotherapy once daily in patients with glaucoma or ocular hypertension.
IRB Protocol #:
H-10145
|
|
Disease/ Subspecialty:
Glaucoma
Principal Investigator:
Ronald Gross, M.D.
Contact:
email Glaucoma-trials@bcm.tmc.edu
or call (713) 798-4123
Enrollment:
No
Sponsor:
Allergan
Title:
A multi-center, double-masked, randomized, parallel extension study evaluating the safety and efficacy of AGN1920240.03% ophthalmic solution compared with Timolol 0.5% ophthalmic solution in patients with glaucoma or ocular hypertension.
IRB Protocol #:
H-7346
|
|
Disease/ Subspecialty:
Glaucoma
Principal Investigator:
Ronald Gross, M.D.
Contact:
email Glaucoma-trials@bcm.tmc.edu
or call (713) 798-4123
Enrollment:
No
Sponsor:
National Eye Institute
Title:
Collaborative initial glaucoma treatment study (CIGTS)
IRB Protocol #:
H-591
|
|
Disease/ Subspecialty:
Glaucoma
Principal Investigator:
Ronald Gross, M.D.
Contact:
email Glaucoma-trials@bcm.tmc.edu
or call (713) 798-4123
Enrollment:
No
Sponsor:
National Eye Institute
Title:
Ocular hypertension treatment study (OHTS)
IRB Protocol #:
H-11333
|
|
Disease/ Subspecialty:
Glaucoma
Principal Investigator:
Silvia Orengo-Nania, M.D.
Contact:
email Glaucoma-trials@bcm.tmc.edu
or call (713) 798-4123
Enrollment:
Yes
Sponsor:
Alcon
Title:
A three-month, randomized, double-masked, parallel group, primary therapy study, with a planned nine-month extension, of the safety and IOP-lowering efficacy of Brimonidine Tartrate ophthalmic solution 0.15% compared to Alphagan P, 0.15% in patients with open-angle glaucoma or ocular hypertension.
IRB Protocol #:
H-13201
|
|
